Hillevax Inc

NASDAQ:HLVXUnited States

HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Contact Information

Headquarters

321 Harrison Ave, Suite 500BOSTON, MA, United States 02118

Phone

617-213-5054

Fax

617-213-5054

Executives

Chairman of the Board, President, Chief Executive Officer

Robert Hershberg

Chief Financial Officer

Shane Maltbie

Chief Operating Officer

Sean Mcloughlin

Chief Administrative Officer, General Counsel, Secretary

Paul Bavier

Chief Business Officer, Director

Aditya Kohli